- Home
- MERC vs ALLO Comparison
MERC vs ALLO Comparison
Compare MERC & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MERC
- ALLO
- Stock Information
- Founded
- MERC 1968
- ALLO 2017
- Country
- MERC Canada
- ALLO United States
- Employees
- MERC N/A
- ALLO N/A
- Industry
- MERC Paper
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MERC Basic Materials
- ALLO Health Care
- Exchange
- MERC Nasdaq
- ALLO Nasdaq
- Market Cap
- MERC 271.5M
- ALLO 277.8M
- IPO Year
- MERC 1987
- ALLO 2018
- Fundamental
- Price
- MERC $3.89
- ALLO $1.30
- Analyst Decision
- MERC Hold
- ALLO Strong Buy
- Analyst Count
- MERC 3
- ALLO 9
- Target Price
- MERC $5.33
- ALLO $8.44
- AVG Volume (30 Days)
- MERC 434.8K
- ALLO 3.2M
- Earning Date
- MERC 07-31-2025
- ALLO 08-06-2025
- Dividend Yield
- MERC 7.75%
- ALLO N/A
- EPS Growth
- MERC N/A
- ALLO N/A
- EPS
- MERC N/A
- ALLO N/A
- Revenue
- MERC $1,996,904,000.00
- ALLO N/A
- Revenue This Year
- MERC $2.43
- ALLO N/A
- Revenue Next Year
- MERC $6.12
- ALLO $199.63
- P/E Ratio
- MERC N/A
- ALLO N/A
- Revenue Growth
- MERC N/A
- ALLO N/A
- 52 Week Low
- MERC $3.20
- ALLO $0.86
- 52 Week High
- MERC $8.57
- ALLO $3.78
- Technical
- Relative Strength Index (RSI)
- MERC 58.53
- ALLO 46.23
- Support Level
- MERC $3.52
- ALLO $1.13
- Resistance Level
- MERC $4.04
- ALLO $1.26
- Average True Range (ATR)
- MERC 0.16
- ALLO 0.08
- MACD
- MERC 0.06
- ALLO -0.00
- Stochastic Oscillator
- MERC 76.92
- ALLO 43.18
About MERC Mercer International Inc.
Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the majority of revenue is generated from the USA. The majority of the revenue is generated from the Pulp segment.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.